Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "BD"

191 News Found

NHA commences first Hackathon under the ‘ABDM Hackathon Series’ in Pune
News | July 18, 2022

NHA commences first Hackathon under the ‘ABDM Hackathon Series’ in Pune

ABDM Hackathon Round 1 – Kickstarting Unified Health Interface (UHI) is being held from 14th to 17th July 2022 as a hybrid event


CerTest Biotec and BD collaborates for molecular diagnostic test for Monkeypox
Diagnostic Center | June 08, 2022

CerTest Biotec and BD collaborates for molecular diagnostic test for Monkeypox

CerTest Biotec uses the BD MAX molecular diagnostic system open system reagent suite to develop RT-PCR detection kit


NHA launches online public dashboard for Ayushman Bharat Digital Mission (ABDM)
News | May 30, 2022

NHA launches online public dashboard for Ayushman Bharat Digital Mission (ABDM)

The ABDM public dashboard is a one-stop solution for information on the mission’s progress up to state/UT level


BDR Pharma receives Rs. 685 crore of PE investment
News | May 17, 2022

BDR Pharma receives Rs. 685 crore of PE investment

Multiples is the first private equity (PE) investor in the company


BDR Pharmaceuticals launch Furmecil to treat advanced gastric cancer
Drug Approval | April 20, 2022

BDR Pharmaceuticals launch Furmecil to treat advanced gastric cancer

The launch is yet another first of its kind innovation in India


BDR Pharma launches enzalutamide in 160 mg strength
Biotech | February 28, 2022

BDR Pharma launches enzalutamide in 160 mg strength

This medicine was previously available in 40mg and 80mg strength, for which patients had to consume 2 tablets a day as per the approved dosage


cbdMD becomes first American CBD brand to receive UK validation
Biotech | February 19, 2022

cbdMD becomes first American CBD brand to receive UK validation

The company will now be allowed to sell its proprietary and validated tinctures, gummies, and capsules across the UK


BDR plans to enter the regulated markets this year: Raheel Shah, Director, BDR Group of Companies
interviews | February 15, 2022

BDR plans to enter the regulated markets this year: Raheel Shah, Director, BDR Group of Companies

BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post


BDR Pharmaceuticals launch Cabozantinib to treat thyroid cancer
Drug Approval | September 14, 2021

BDR Pharmaceuticals launch Cabozantinib to treat thyroid cancer

In several trials like Celestial (double-blind phase III trial), Phase III Meteor trials, Cabozantinib has shown better PFS (Progression-Free Survival).


SAB Biotherapeutics nonclinical data indicates SAB-185 neutralizes Delta and Lambda SARS-CoV-2 Variants
Drug Approval | August 12, 2021

SAB Biotherapeutics nonclinical data indicates SAB-185 neutralizes Delta and Lambda SARS-CoV-2 Variants

SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial